Assessing the risk of cervical neoplasia in the post-HPV vaccination era

Matti Lehtinen, Ville N. Pimenoff, Belinda Nedjai, Karolina Louvanto, Lisanne Verhoef, Daniëlle A. M. Heideman, Mariam el-Zein, Martin Widschwendter, Joakim Dillner

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)


This review is based on the recent EUROGIN scientific session: “Assessing risk of cervical cancer in the post-vaccination era,” which addressed the demands of cervical intraepithelial neoplasia (CIN)/squamous intraepithelial lesion (SIL) triage now that the prevalence of vaccine-targeted oncogenic high-risk (hr) human papillomaviruses (HPVs) is decreasing. Change in the prevalence distribution of oncogenic HPV types that follows national HPV vaccination programs is setting the stage for loss of positive predictive value of conventional but possibly also new triage modalities. Understanding the contribution of the latter, most notably hypermethylation of cellular and viral genes in a new setting where most oncogenic HPV types are no longer present, requires studies on their performance in vaccinated women with CIN/SIL that are associated with nonvaccine HPV types. Lessons learned from this research may highlight the potential of cervical cells for risk prediction of all women's cancers.
Original languageEnglish
JournalInternational journal of cancer
Early online date2022
Publication statusE-pub ahead of print - 2022


  • cervical cancer
  • epigenetics
  • gynecological cancers
  • human papillomavirus
  • methylation

Cite this